


IntracrySTALLine Ozurdex® implant: iatrogenic intravitreal injection management

Search for articles by this author



The intravitreal dexamethasone implant Ozurdex® (Allergan, Inc, Irvine, Calif.) is indicated for the treatment of diabetic macular edema, venous occlusion of the retinal vessels, and noninfectious uveitis. In phakic patients, it is suggested that the injection should be done 4 mm posterior to the corneal limbus, directing the needle to the optic nerve, preferably in the inferotemporal quadrant. Although it

is a rare event, inadvertent intracryalline injection of the dexamethasone implant has been reported in the literature and can lead to complications such as cataract, glaucoma, and visual impairment.

To read this article in full you will need to make a payment

Article info

Publication history

Published online: October 04, 2021

Accepted: August 11, 2021

Received: August 4, 2021

Identification

DOI: <https://doi.org/10.1016/j.jcjo.2021.08.009>

Copyright

© 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles